About Auxilium Pharmaceuticals, Inc (NASDAQ: AUXL)

About Auxilium Pharmaceuticals, Inc (NASDAQ: AUXL)

40 Valley Stream Parkway
Malvern, PA 19355

(484) 321-5900


23-3016883
(I.R.S. Employer
Identification No.)

Employees: 540 (Approx.)

Revenue: $ 164 Million


From Form 10-K,

"We are a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists. We currently have approximately 540 employees, including a sales and marketing organization of approximately 315 people. We reported revenues in 2009 of $164 million, an increase of 30.8% over the $125.4 million reported in 2008.

We currently market two products in the United States (“U.S.”):

Testim® is a proprietary, topical 1% testosterone once-a-day gel indicated for the treatment of hypogonadism. Hypogonadism is defined as reduced or absent secretion of testosterone which can lead to symptoms such as low energy, loss of libido, adverse changes in body composition, irritability and poor concentration. Testim has been approved in the U.S. by the U.S. Food and Drug Administration (“FDA”) and according to National Prescription Audit (“NPA”) data from IMS Health, Inc. (“IMS”), a pharmaceutical market research firm, Testim’s share of total prescriptions for the gel segment of the U.S. testosterone replacement therapy (“TRT”) market was 22.3% for the month of December 2009, and 22.0% for the full year 2009.

XIAFLEX™ (collagenase clostridium histolyticum) is a proprietary, injectable collagenase enzyme for the treatment of Dupuytren’s contracture (“Dupuytren’s”). XIAFLEX received approval from the FDA on February 2, 2010 for the treatment of adult Dupuytren’s patients with a palpable cord. Dupuytren’s is a condition that affects the connective tissue that lies beneath the skin in the palm. The disease is progressive in nature. Typically, nodules develop in the palm as collagen deposits accumulate. As the disease progresses, the collagen deposits form a cord that stretches from the palm of the hand to the base of the finger. Once this cord develops, the patient’s fingers contract and the function of the hand is impaired. Prior to approval of XIAFLEX, surgery was the only effective treatment. We expect to begin shipping XIAFLEX to our distribution partners in early March 2010 in advance of a launch planned for the end of March 2010.

We also have received marketing approval for Testim in Belgium, Canada, Denmark, Finland, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom (“U.K.”). Ferring International Center S.A. (“Ferring”) and Paladin Labs Inc. (“Paladin”) commercialize Testim on our behalf in certain European countries and Canada, respectively.

Our current product pipeline includes:

Phase II:

XIAFLEX for the treatment of Peyronie’s disease (“Peyronie’s”)

XIAFLEX for the treatment of Adhesive Capsulitis (“Frozen Shoulder syndrome”)

Phase I:

AA4010, treatment for overactive bladder using our transmucosal film delivery system

A Fentanyl pain product using our transmucosal film delivery system.

In addition to the above, we have the rights to develop other compounds for the treatment of pain using our transmucosal film delivery system and other products using our transmucosal film technology for treatment of urologic disease and for hormone replacement. We also have the option to license additional indications for XIAFLEX other than dermal products for topical administration.





200 Largest Pharmaceutical companies
http://flucrazy.blogspot.com/2011/02/flucrazy-200-200-largest-pharmaceutical.html